The cold winter has passed, and the half-year performance of five listed vaccine companies ushered in a "big counterattack"!

In the first half of last year, affected by the "vaccine incident", domestic second-class vaccine manufacturers suffered "Waterloo" in performance At that time, the performance of Zhifei biology fell sharply, and Watson biology lost more than 100 million yuan This year, with the elimination of the impact of the "vaccine incident", a number of vaccine companies, such as Zhifei biology and Watson biology, ushered in a performance counterattack Among them, the business income of Zhifei biology, Kangtai biology and Changsheng biology increased by more than 100% year on year Table 1: the performance of five vaccine companies in the first half of 2017 (unit: 10000 yuan) none = "shifumousedownstyle ('shifu bus_ ')" style = "margin: 1em Auto; padding: 0px; max width: 100%; color: rgb (62, 62, 62); font family:" hiragino sans GB "," Microsoft YaHei ", Arial, sans serif; font size: 16px; line height: 25.6px; width: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> Zhifei biology: net profit increased by 1326.96% year-on-year; in the first half of 2017, Zhifei biology's operating revenue was 445.16 million yuan, an increase of 142.01% year-on-year; net profit attributable to shareholders of listed companies was 171.79 million yuan, an increase of 1326.96% year-on-year Zhifei said that the company's main business income mainly comes from the sales of class II vaccines The uncertainties caused by last year's events in the vaccine industry are gradually being eliminated, the new policies of the industry have been gradually implemented, and the sales of class II vaccines have been resumed Table 2: batch issuance of main products of Zhifei biology in the first half of the year (unit: 10000 pieces) The company has 5 kinds of independent products on sale, including AC Hib vaccine, acyw135 meningococcal polysaccharide vaccine, Hib vaccine, AC meningococcal polysaccharide combined vaccine, micro card, and 3 kinds of promotion or agent products on sale, respectively, Zhejiang Pukang's live attenuated hepatitis A vaccine and MSD's 23 valent pneumonia and inactivated hepatitis A vaccine Among them, the growth rate of wholesale signing volume of four kinds of independent products listed in Table 2 in the first half of 2017 was amazing, all of which exceeded 100% In addition, Gardasil, the exclusive agent of Zhifei biological, obtained the drug registration approval document in the mainland in May this year At present, Gardasil has won the bid in Yunnan Province, and the bidding work in other provinces of the country is advancing in an orderly manner It is expected to be officially sold in 2018 According to the agreement signed between the company and MSD, the basic procurement plan of HPV vaccine is about 1.14 billion yuan in the first year, 1.483 billion yuan in the second year and 1.853 billion yuan in the third year After the product is officially put on the market, it will bring huge profits to the company   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> Watson Bio: the net profit decreased by 118.88 million yuan on a year-on-year basis in the first half of 2017, and the operating revenue of Watson bio was 256.7 million yuan, down 12.39% on a year-on-year basis; the net profit attributable to shareholders of listed companies was - 43.01 million yuan, down 118.88 million yuan on a year-on-year basis, up 73.43% on a year-on-year basis, and 15.58 million yuan on a year-on-year basis in the second quarter Watson Bio said that the main reason for the loss was that the company actively expanded its vaccine sales business, enabling the sales revenue and net profit of its own vaccine products to achieve a synchronous growth It is worth mentioning that the 23 price pneumococcal polysaccharide vaccine of Watson biological new product has been approved and officially put on the market at the end of July, and is expected to form a new revenue and profit growth point of the company in the third quarter of this year Table 3: Sales of Watson biological's autonomous vaccine in the first half of the year: (unit: 10000 yuan) at present, the company's main production and sales of autonomous vaccine products are: Hib vaccine (vials and pre potting), freeze-dried group AC meningococcal polysaccharide combined vaccine, group acyw135 meningococcal polysaccharide vaccine and group a group C meningococcal polysaccharide vaccine In the first half of 2017, the company's independent product business recovered and its performance improved significantly, of which the sales revenue of independent vaccine products increased by 88.85% year-on-year compared with 2016, and the second quarter of 2017 increased by 194.65% month on month compared with the first quarter none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> Kangtai biology: revenue increased by 128.72% year on year table 4: Sales of products in the first half year of Kangtai biology: (unit: 10000 yuan) in the first half year of 2017, Kangtai biology's operating revenue was 469.31 million yuan, an increase of 128.72% year on year; net profit attributable to shareholders of listed companies was 70.55 million yuan, an increase of 25.79% year on year Among them, the sales of class I vaccine was 38.9 million yuan, accounting for 8.29% of the total revenue; while the sales of class II vaccine was 429.25 million yuan, up 191.99% year-on-year, accounting for 91.46% of the total revenue According to Kangtai biology, the main reasons for the rapid growth of income and profit are: 1) after the reform of vaccine circulation, it became a one vote system, the vaccine factory was opened high and the price was generally raised, which led to a significant increase in income and the company's profitability; 2) Shandong vaccine event led to a low base last year, with a significant year-on-year growth At present, the company has four kinds of products on sale, including hepatitis B vaccine, Hib vaccine, leprosy vaccine, and quadruple vaccine Among them, the technology content of genetic engineering vaccine (hepatitis B vaccine) and combined vaccine (quadruple vaccine) is relatively high The 60 μ g recombinant hepatitis B vaccine (Saccharomyces cerevisiae) and quadruple vaccine of the company are currently exclusive products in China, with a promising market potential   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> Changsheng biology: revenue and net profit increased by 106% year-on-year Table 5: Sales of products of Changsheng biology in the first half of 2017: (unit: 10000 yuan) the operating revenue of Changsheng biology in the first half of 2017 was 629.8 million yuan, an increase of 106.08% year-on-year; the net profit attributable to shareholders of listed companies was 264.26 million yuan, an increase of 106.16% year-on-year Among them, the sales of class I vaccine was 62.46 million yuan, accounting for 9.92% of the total revenue; while the sales of class II vaccine was 56.18 million yuan, up 132.07% year on year, accounting for 89.20% of the total revenue At present, the products on sale include freeze-dried live attenuated varicella vaccine, freeze-dried human rabies vaccine (Vero cell), freeze-dried live attenuated hepatitis A vaccine, influenza split vaccine, combined cell-free pertussis vaccine and acyw 135 group meningococcal polysaccharide vaccine In the first half of 2017, Changchun Changsheng, a subsidiary of Changsheng biology, carried out the production and application of tetravalent influenza vaccine (adult type), completed the phase I and phase II clinical research of live attenuated herpes zoster vaccine, and is currently carrying out the phase III clinical work In addition, Changchun Changsheng and the Institute of Microbiology of the Chinese Academy of sciences have officially signed a technology transfer agreement for the research and development of new Zika vaccine in the first half of 2017 Changchun Changsheng has transferred the proprietary technology for the preparation of new Zika inactivated vaccine of the Institute of Microbiology with RMB 15 million By signing a technology transfer agreement with the Institute of Microbiology, it will be beneficial to accelerate the research and development progress of Changchun Changsheng Zika vaccine   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border-style: none none solid; text-align: center; border-bottom-width: 1px; Border bottom color: rgb (0, 0, 0); box side: border box! Im portant; word wrap: break word! Im portant; "> Chengda biology: steady performance growth Liaoning Chengda biology achieved operating revenue of 584.6 million yuan in the first half of 2017, a year-on-year growth of 24.72%; net profit attributable to shareholders of listed companies was 262.22 million yuan, a year-on-year growth of 10.27% According to Chengda biology, the company's operating performance has increased significantly, mainly due to the adjustment of the company's marketing model, the ex factory price of vaccine products has been improved, during which the market of human B vaccine has recovered, the sales volume has increased year on year, the sales volume of foreign human rabies vaccine has increased substantially year on year, and the gradual increase of product volume and price has helped the company's operating revenue and net profit achieve a large growth Table 6: Sales of major products of Chengdu bio in the first half of the year: (unit: 10000 yuan) Liaoning Chengdu bio's main business is R & D, production and sales of human vaccines At present, the company's main products include human rabies vaccine (Vero cell), human JE inactivated vaccine (Vero cell) Among them, rabies vaccine includes rabies vaccine water needle and rabies vaccine freeze-dried The total sales revenue of the two vaccines in the first half of the year reached 509.29 million yuan In addition, the company's diploid hepatitis A vaccine has been approved for clinical trials, and other vaccine research and development are progressing smoothly It is worth mentioning that, in compliance with the requirements of the new regulations on vaccines and changes in vaccine distribution channels, Chengda biology took the lead in establishing a cold chain logistics system for trunk transportation and regional storage and distribution, which was highly recognized by the government regulatory authorities and promoted in the industry none="shifuMouseDown('shifu_t_002')" style="margin: 1em auto; padding: 0.5em 0px; max-width: 100%; color: rgb(62, 62, 62); font-family: "Hiragino Sans GB", "Microsoft YaHei", Arial, sans-serif; font-size: 16px; line-height: 25.6px; widows: 1; border: none; text-align: center; width: 670px; box-sizing: border-box !im portant; word-wrap: break-word ! im portant; "> conclusion 2017 is a year of opportunities and challenges for vaccine enterprises The impact of" vaccine event "is fading, and the growth potential of vaccine industry is huge The implementation of new policies in the industry also puts forward higher regulatory requirements for vaccine enterprises At present, the residents' disposable income and awareness of disease prevention are increasing, the two child policy has brought baby booms, the investment in vaccine research and development and production is increasing, and the products are upgrading gradually, all of which indicate that the domestic vaccine industry will achieve rapid growth Therefore, vaccine enterprises should accurately grasp the market trend, take the change of industry policy and the development plan of national drug field as the guidance, timely adjust the strategy, pay attention to the combination of strategic guidance and market guidance, actively change the sales mode, increase the market development, constantly expand the brand influence, and realize the steady growth of business performance Source: semi annual report of listed company